Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
Portfolio Pulse from Vandana Singh
The U.S. Federal Trade Commission (FTC) has approved Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics Plc. The FTC had previously objected to the deal, but suspended its opposition in late August. The acquisition will give Amgen access to Horizon's rare disease assets, including the thyroid eye disease therapy Tepezza. As part of the settlement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa, Horizon's gout medication.
September 01, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's acquisition of Horizon Therapeutics has been approved by the FTC. This could potentially boost Amgen's portfolio with Horizon's rare disease assets.
The FTC's approval of the acquisition could potentially boost Amgen's portfolio with Horizon's rare disease assets, which could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Horizon Therapeutics' acquisition by Amgen has been approved by the FTC. This could potentially lead to increased resources and support for Horizon's products.
The FTC's approval of the acquisition could potentially lead to increased resources and support for Horizon's products, which could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100